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Abstract
Background: Statins have been reported to prevent adverse cardiovascular events in patients with myocardial
infarction (MI). However, the association of statin use and the risk of pneumonia requiring hospitalization in MI
patients remains unclear.
Methods: A nested case-control study was conducted by using data from the National Health Insurance Research
Database of Taiwan. Among 24,975 patients with MI, 2686 case patients with pneumonia requiring hospitalization
were age- and sex-matched with 10,726 control patients using the incidence density sampling approach. Duration
and dosage of statin use were obtained from pharmaceutical claims. Conditional logistic regression analyses were
used to estimate the risk of hospitalization for pneumonia associated with statin use adjusted for patient’s
demographics, medical conditions and prescribed medications.
Results: Statin use was associated with a 15 % reduced risk of pneumonia requiring hospitalization among MI
patients (adjusted odds ratio [aOR] = 0.85, 95 % confidence interval [CI] = 0.77–0.95, P = 0.004). The association was
more significant for MI patients unexposed to statin pretreatment (aOR = 0.76, 95 % CI = 0.64–0.90, P = 0.001). Statins
also exhibited favorable benefits in a time- and dose-dependent manner. The results were consistent in various
subgroup analysis of the patients who were female, age ≥ 65 years, a low CHADS2 (i.e. congestive heart failure,
hypertension, diabetes mellitus, previous stroke and age > 75 years old) score, and fewer comorbidities. Atorvastatin,
fluvastatin and simvastatin were the most common prescribed statins and had similar effects.
Conclusions: Statins might be considered as an adjunctive therapy to reduce the risk of hospitalization for
pneumonia for MI patients under thorough evaluation of individual comorbidities, previous statin use and optimal
dosage.
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Background
Myocardial infarction (MI) is the most acute and severe
presentation of ischemic heart disease. Approximately
620,000 people have a new coronary attack each year in
the United States, and 15 % of those do not survive the
event [1, 2]. Besides, survivors of MI have a higher
chance of illness and death from cardiac or noncardiac
causes compared with the general population [1–3]. Pa-
tients with MI had a 79 % increased risk of incident in-
fection compared with those without an MI history, and
the most frequent infection was pneumonia [3]. Add-
itionally, MI patients had a significantly higher rate of
all-cause mortality during the course of pneumonia than
that of patients without a history of MI [4]. Therefore,
strategies for preventing the development of adverse car-
diovascular events and incident pneumonia among pa-
tients with MI are crucial.
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Statins are competitive inhibitors of 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase, a
rate-limiting enzyme of the cholesterol biosynthesis
pathway [5], and are commonly used in the primary and
secondary prevention of atherosclerotic cardiovascular
diseases [6]. Previous researches have also demonstrated
that statin pretreatment improves the clinical outcomes
of MI [7, 8]. Recently, epidemiological studies have
shown that statins have pleiotropic effects, resulting in a
reduced risk of incident pneumonia in the general popu-
lation as well as patients with diabetes [9–12]. However,
whether statin use is associated with a reduced risk of
pneumonia in MI patients who are at high cardiovascu-
lar risk and susceptible to pneumonia remains unclear.
The aim of this study was to investigate the association
between statin use and pneumonia hospitalization
among patients with a history of MI. We conducted a
nested case–control study by using data from the Na-
tional Health Insurance Research Database (NHIRD) of
Taiwan. Subgroup analysis was performed to identify the
aforementioned association among patients with differ-




This retrospective observational research was approved
by the Joint Institutional Review Board of Taipei Medical
University (TMU-JIRB No. 201404055). Data from the
NHIRD was provided by the National Health Insurance
Administration (NHIA) of Taiwan that covers 99 % of
residents in Taiwan under the legislation of National
Health Insurance (NHI). To protect the privacy of
beneficiaries, individual identifiers have been encrypted
before data are released to researchers. Consequently,
informed consent of the participants was exempted
under the full review process of the Joint Institutional
Review Board of Taipei Medical University.
Study design and data source
This nested case-control study was conducted by using
data from NHIRD which were collected between 2000
and 2011. The NHIRD files contained International
Classification of Diseases, Ninth Revision, Clinical Modi-
fication (ICD-9-CM) disease diagnosis codes, treatment
procedures, date of service, reimbursement amounts,
demographic information on beneficiaries and benefi-
ciary- and provider-encrypted identifiers. Claims for pre-
scribed drugs were also provided and could be classified
according to the Anatomical Therapeutic Chemical (ATC)
classification system. To verify the accuracy of diagnoses
and the rationale for treatments, the NHIA routinely
samples a proportion of the NHI claims. Additionally,
hospitals and clinics are penalized if they provide any
unnecessary medical treatment to patients [13].
Study cohort
The study cohort consisted of patients who were first
admitted for a primary diagnosis of MI (ICD-9-CM:
410) between the year of 2002 and 2010, and received
prescriptions of statins during MI hospitalization.
We excluded participants who were < 20 years old
or > 80 years old, for whom the sex was unidentified,
and had a history of MI or pneumonia (ICD-9-CM:
480–486) in the preceding 2 years. Figure 1 presents
the patient selection process.
Case ascertainment and control selection
The case patients were those who were readmitted for
the primary diagnosis of incident pneumonia (ICD-9-
CM: 480–486) requiring hospitalization after MI admis-
sion. In Taiwan, the diagnosis of pneumonia at least
must comply with the positive findings of the patient’s
chest X-ray. The date of hospitalization for pneumonia
was defined as the index date. The control patients were
randomly selected by using incidence density sampling
of all patients with MI who were alive and free of pneu-
monia at the time of being observed. Each case patient
was matched to 4 control patients by sex, age ± 1 year,
year of hospitalization for MI, and follow-up period. The
control patients were assigned a pseudo index date of
pneumonia admission, which corresponded to the index
date of their matched cases.
Statin exposure
Statin use was determined based on prescription claims
in the NHIRD. The duration of statin use was defined as
the period between the latest date of prescription and
the index date of pneumonia of case patients or the
pseudo index date of control patients (hereafter, “index
date”). For each patient, the drug prescriptions were
traced back from the index date up to 1 year. Both case
and control patients were categorized into “users” if they
had any statin claim and “nonusers” if they had no statin
claims 1 year before the index date. Subsequently, the
users were further classified into “current users” for 0–
90 days, “recent users” for 91–180 days, or “former
users” for >180 days. The dose-response effect was
assessed based on the defined daily dose (DDD), which
is the assumed maintenance dose per day for adults rec-
ommended by the World Health Organization [14], and
was classified as < 0.5, 0.5–1.0, and > 1.0 of the DDD
within a 90-day period (DDD90). Additionally, we per-
formed analyses to compare the effects of different sta-
tins among the patients with statin prescription within a
90-day period before the index date. A specific statin
was defined if it was the nearest and longest statin to
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the index date. The DDDs of the statins considered in
our study are provided in Additional file 1: Table S1.
Potential confounding variables
Previous or coexisting medical conditions were recorded
if the patients had ≥ 2 diagnostic claims for diabetes mel-
litus (DM), hypertension (HTN), congestive heart failure
(CHF), stroke, asthma, chronic obstructive pulmonary
disease (COPD), chronic kidney disease (CKD), chronic
liver disease (CLD), Parkinson disease or dementia. We
also considered and controlled for the CHADS2 score,
which is the sum of the risk factors for CHF, HTN, DM
and stroke as well as the age > 75 years at the diagnosis
of MI. The CHADS2 score was initially used to predict
the risk of stroke in patients with nonvalvular atrial fib-
rillation [15], and has been proposed recently for pre-
dicting the prognosis of patients with acute coronary
syndrome [16, 17]. The history of influenza and pneu-
monia vaccination and prescribed medications before
the index date were further adjusted. For each patient,
the records of medical conditions and medications were
traced from the index date up to 1 year. Detailed infor-
mation on ICD-9-CM diagnosis codes and the ATC clas-
sification system codes are provided in Additional file 2:
Table S2 and Additional file 3: Table S3, respectively.
Statistical analyses
The primary analysis was to examine the association be-
tween statin use and the risk of pneumonia requiring
hospitalization. To investigate the effect of statin pre-
treatment before an MI event, the secondary analysis
was limited to MI patients unexposed to statin pretreat-
ment. The stratified analysis of the patients with a spe-
cific characteristic was also performed. For all variables
of interest, risk estimates were computed as both univar-
iate and multivariate analyses, with additional adjust-
ments for potential confounders. Conditional logistic
regression was used to estimate unadjusted and adjusted
odds ratios (ORs) and 95 % confidence intervals (CIs)
for the association of statin exposure and the risk of
hospitalization for pneumonia; and the incidence density
sampling yields ORs that are interpretable as unbiased
estimates of the incidence ORs [18, 19]. All analyses
were performed using SAS/STAT 9.3 (SAS Institute Inc.,
Cary, NC, USA) and STATA 12 (Stata Corp LP, College
Station, TX, USA); P < 0.05 was considered significant.
Results
Of the 24,975 patients with a history of MI, we identified
2686 case patients who were hospitalized for pneumonia
and 10,726 control patients who were not hospitalized
Fig. 1 Flow diagram of patient selection. MI = myocardial infarction
Lin et al. BMC Cardiovascular Disorders  (2016) 16:24 Page 3 of 10
for pneumonia (Fig. 1). Compared with the control pa-
tients, the case patients had higher CHADS2 scores
(CHADS2 scores ≥ 1: case 36.6 %; control 17.7 %), and
higher rates of previous or coexisting DM, HTN, CHF,
stroke, asthma, COPD, CKD, CLD and dementia. In
addition, the case patients were more likely to use anti-
neoplastic drugs, proton pump inhibitors (PPIs), ste-
roids, angiotensin converting enzyme inhibitor and
angiotensin receptor blockade (ACEI/ARBs), immuno-
suppressants, immunostimulants and nitrates compared
with the control patients (Table 1).
The percentage of any use of statins among the case
and control patients was 68.9 and 71.6 %, respectively.
Statin use was associated with a 15 % reduced risk of
incident pneumonia requiring hospitalization after we
controlled for all risk factors (aOR 0.85, 95 % CI 0.77–
0.95, P = 0.004) (Table 2). Additionally, the timing of statin
use for the case patients significantly differed from that
for the control patients (Table 2). The odds of current
users for the case patients were lower than that for the
control patients (aOR 0.75, 95 % CI 0.67–0.85, P < 0.001).
We also observed that the DDD90 was associated with
a dose-dependent manner that the benefits of statin to
prevent the occurrence of pneumonia were deter-
mined when the DDD90 was ≥ 0.5. However, the pro-
tective effect of a DDD90 of 0.5–1.0 (aOR 0.75, 95 % CI
0.66–0.84, P < 0.001) was closed to that of a DDD90 ≥ 1.0
(aOR 0.74, 95 % CI 0.63–0.87, P = 0.002) (Table 2).
Table 1 Baseline characteristics of case patients with pneumonia and control patients
Controls Cases
Variables N (%) N (%) Crude OR (95 % CI) P
Sample size 10,726 (100.0) 2,686 (100.0)
Female 3,280 (30.6) 824 (30.7)
Age (y) Mean (± SD) 67.1 (±10.0) 67.1 (±10.0)
CHADS2 score
0 8,830 (82.3) 1,703 (63.4) 1.00 (Ref.)
1–2 1,695 (15.8) 838 (31.2) 3.33 (2.99–3.71) <0.001
> 2 201 (1.9) 145 (5.4) 5.85 (5.03–6.79) <0.001
Comorbidities, yes (Ref. = No)
Diabetes mellitus 800 (7.5) 552 (20.6) 3.33 (2.94–3.76) <0.001
Hypertension 418 (3.9) 268 (10) 2.77 (2.36–3.26) <0.001
Congestive heart failure 800 (7.5) 570 (21.2) 3.43 (3.04–3.87) <0.001
Stroke 1,372 (12.8) 654 (24.3) 2.21 (1.98–2.45) <0.001
Asthma 133 (1.2) 74 (2.8) 2.28 (1.70–3.04) <0.001
COPD 246 (2.3) 196 (7.3) 3.43 (2.82–4.18) <0.001
Chronic kidney disease 118 (1.1) 108 (4) 3.76 (2.88–4.91) <0.001
Chronic liver disease 28 (0.3) 16 (0.6) 2.29 (1.23–4.22) 0.008
Parkinson disease 20 (0.2) 8 (0.3) 1.60 (0.70–3.63) 0.260
Dementia 49 (0.5) 24 (0.9) 1.96 (1.20–3.19) 0.007
Medication use, yes (Ref. = No)
Antineoplastic drug 67 (0.6) 71 (2.6) 4.35 (3.10–6.10) <0.001
PPI 1,127 (10.5) 665 (24.8) 2.86 (2.56–3.19) <0.001
Steroid 1,756 (16.4) 736 (27.4) 1.96 (1.77–2.16) <0.001
ACEI/ARB 5,983 (55.8) 1,674 (62.3) 1.33 (1.21–1.45) <0.001
Antiviral drug 143 (1.3) 47 (1.7) 1.32 (0.95–1.84) 0.100
Immunosuppressants 19 (0.2) 12 (0.4) 2.53 (1.22–5.20) 0.010
Immuostimulants 7 (0.1) 8 (0.3) 5.01 (1.72–14.5) 0.003
Nitrate 6,277 (58.5) 1,847 (68.8) 1.62 (1.47–1.78) <0.001
Antiplatelet 9,151 (85.3) 2,330 (86.7) 1.13 (0.99–1.28) 0.050
Vaccine (influenza or pneumococcal) 2,551 (23.8) 631 (22.8) 0.94 (0.85–1.05) 0.280
ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blockade, CHADS2 congestive heart failure, hypertension, age > 75 years, diabetes, previous
stroke, CI confidence interval, COPD chronic obstructive pulmonary disease, OR odds ratio, PPI proton pump inhibitor, Ref reference group, SD standard deviation
Lin et al. BMC Cardiovascular Disorders  (2016) 16:24 Page 4 of 10
Of the patients who were unexposed to statin pre-
treatment at the time of being diagnosed with MI, we
identified 1313 case patients who were hospitalized for
pneumonia and 6321 control patients who were not
hospitalized for pneumonia. The percentage of any use
of statins among the case and control patients was 60.4
and 66.3 %, respectively. Among patients unexposed to
pretreatment, statin users had a 24 % decreased risk of
pneumonia hospitalization (aOR 0.76, 95 % CI 0.64–
0.90, P = 0.001). The results of current users and dos-
age manner were consistent with the findings of the
primary analysis, but the association was stronger
(Table 3).
We performed a stratified analysis and redefined “statin
users” if patients had a statin of DDD90 ≥ 0.5. Our results
showed a negative association between statin exposure
and the risk of pneumonia requiring hospitalization in the
patients who were female, were aged ≥ 65 years, had lower
CHADS2 scores (0 or 1), or had no history of DM, HTN,
CHF, asthma or COPD (Fig. 2).
The major statins used within a 90-day period prior
to the index date were atorvastatin, fluvastatin and
simvastatin (Table 4). For all patients with MI, fluvas-
tatin and simvastatin had similar associations with the
risk of pneumonia requiring hospitalization compared
to atorvastatin (fluvastatin: aOR 1.14, 95 % CI 0.85–
1.52, P = 0.390; simvastatin: aOR 1.19, 95 % CI 0.87–
1.64, P = 0.283). For patients unexposed to statin
pretreatment, the results were consistent with the findings
of overall MI patients.
Discussion
In this nested case-control study, we observed that statin
use in MI patients was associated with a 15-25 % re-
duced risk of pneumonia requiring hospitalization. We
also observed that the benefits of statins were particu-
larly marked for current users who used statins within
90 days and for those who used statins of ≥ 0.5 DDD90.
In addition, the favorable effect was shown in the pa-
tients who were female, were aged ≥ 65 years, and had
no history of cardiovascular and respiratory diseases.
Atorvastatin, fluvastatin and simvastatin were the most
common prescribed statins and had similar effects on re-
ducing the risk of pneumonia requiring hospitalization.
The effect of statin use on reducing the occurrence of
pneumonia has been shown in the general population
[10, 11]. In this present study, we additionally found that
statin use might also have a favorable effect on decreas-
ing pneumonia hospitalization in MI patients who were
more susceptible to pneumonia and had more comor-
bidities compared to general population. However, this
favorable effect was not significant when the analysis
was limited to MI patients with a higher CHADS2 score
(CHADS2 score ≥ 2). Some unmeasured differences in
baseline characteristics might still exist in statin users
and nonusers, resulting in overestimating the benefits of
Table 2 Association between statin use and the risk of pneumonia requiring hospitalization
Controls Cases Crude OR Adjusteda OR
N (%) N (%) (95 % CI) P (95 % CI) P
Sample size 10,726 (100.0) 2,686 (100.0) - -
Statin measurement
Any statin≤ 365 d
Non-user 3,041 (28.4) 835 (31.1) 1.00 (Ref.) 1.00 (Ref.)
User 7,685 (71.6) 1,851 (68.9) 0.87 (0.78–0.95) 0.003 0.85 (0.77–0.95) 0.004
By recency
Non-user 3,041 (28.4) 835 (31.1) 1.00 (Ref.) 1.00 (Ref.)
≤ 90 d (current) 4,778 (44.5) 963 (35.9) 0.72 (0.64–0.80) <0.001 0.75 (0.67–0.85) <0.001
91–180 d (recent) 697 (6.5) 229 (8.5) 1.17 (0.98–1.39) 0.080 1.06 (0.87–1.28) 0.570
>180 d (former) 2,210 (20.6) 659 (24.5) 1.08 (0.96–1.23) 0.190 0.98 (0.86–1.12) 0.810
By DDD90
Non-user 3,041 (28.4) 835 (31.1) 1.00 (Ref.) 1.00 (Ref.)
≤ 0.5 DDD90 1,278 (11.9) 388 (14.4) 1.05 (0.92–1.19) 0.510 0.98 (0.85–1.13) 0.760
0.5-1 DDD90 2,808 (26.2) 539 (20.1) 0.66 (0.59–0.74) <0.001 0.75 (0.66–0.84) <0.001
> 1 DDD90 1,389 (12.9) 265 (9.9) 0.66 (0.57–0.76) <0.001 0.74 (0.63–0.87) 0.002
ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blockade, CHADS2 congestive heart failure, hypertension, age > 75 years, diabetes, previous
stroke, CI confidence interval, COPD chronic obstructive pulmonary disease, DDD defined daily dose, DDD90 average defined daily dose within 90 days, OR odds
ratio, PPI proton pump inhibitor, Ref reference group, SD standard deviation
a Adjusted for CHASD2 score, medical conditions (diabetes mellitus, hypertension, chronic heart failure, stroke, COPD, chronic kidney disease, chronic liver disease,
Parkinson disease, and dementia) and medication use (antineoplastic drug, PPI, ACEI/ARB, antiviral drug, immunosuppressants, immunostimulants, nitrate,
antiplatelet and influenza or pneumococcal vaccine)
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Fig. 2 Subgroup analysis of patients in different comorbidity subgroups. CHADS2 = congestive heart failure, hypertension, age > 75 years, diabetes
mellitus and previous stroke; CHF = congestive heart failure; CI = confidence interval; COPD= chronic obstructive pulmonary disease; DM= diabetes
mellitus; HTN = hypertension; OR = odds ratio
Table 3 Subgroup analysis of patients unexposed to statin pretreatment
Controls Cases Crude OR Adjusteda OR
N (%) N (%) (95 % CI) P (95 % CI) P
Sample size 6,321 (100.0) 1,313 (100.0) - - -
Statin Measurement
Any statin≤ 365 d
Non-user 2,130 (33.7) 520 (39.6) 1.00 (Ref.) 1.00 (Ref.)
User 4,191 (66.3) 793 (60.4) 0.75 (0.65–0.87) <0.001 0.76 (0.64–0.90) 0.001
By recency
Non-user 2,130 (33.7) 520 (39.6) 1.00 (Ref.) 1.00 (Ref.)
≤ 90 d (current) 2,683 (42.4) 403 (30.7) 0.60 (0.51–0.71) <0.001 0.65 (0.54–0.79) <0.001
91–180 d (recent) 376 (5.9) 110 (8.4) 1.16 (0.88–1.52) 0.290 1.20 (0.88–1.64) 0.240
> 180 d (former) 1,132 (17.9) 280 (21.3) 0.97 (0.80–1.18) 0.770 0.84 (0.68–1.05) 0.130
By DDD90
Non-user 2,130 (33.7) 520 (39.6) 1.00 (Ref.) 1.00 (Ref.)
≤ 0.5 DDD90 757 (12.0) 178 (13.6) 0.99 (0.80–1.22) 0.900 0.99 (0.78–1.27) 0.960
0.5–1 DDD90 1,574 (24.9) 233 (17.7) 0.61 (0.51–0.73) <0.001 0.73 (0.59–0.89) 0.002
> 1 DDD90 728 (11.5) 102 (7.8) 0.55 (0.43–0.69) <0.001 0.65 (0.50–0.85) 0.001
ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blockade, CHADS2 congestive heart failure, hypertension, age > 75 years, diabetes, previous
stroke, CI confidence interval, COPD chronic obstructive pulmonary disease, DDD defined daily dose, DDD90 average defined daily dose within 90 days, OR odds
ratio, PPI proton pump inhibitor, Ref reference group, SD standard deviation
a Adjusted for CHASD2 score, medical conditions (diabetes mellitus, hypertension, chronic heart failure, stroke, COPD, chronic kidney disease, chronic liver disease,
Parkinson disease, and dementia) and medication use (antineoplastic drug, PPI, ACEI/ARB, antiviral drug, immunosuppressants, immunostimulants, nitrate,
antiplatelet and influenza or pneumococcal vaccine)
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statins on pneumonia hospitalization. For example, pa-
tients who adhered to statin therapy might have other
related preventive behaviors (eg, exercising, avoiding to-
bacco and accessing medical help). Thus, rigorous and
randomized controlled clinical trials are required to
minimize the potential confounding bias and confirm
the preventive effect of statin use on pneumonia
hospitalization.
Our analyses showed some discrepancies about the re-
cency of the benefits of statins compared with the previ-
ous studies. Nielsen demonstrated that statin use within
125 days before index pneumonia had a protective effect
[10]. In another case-control study [11], Vinogradova
demonstrated that the benefit was observed only in pa-
tients who used statin within 28 days before pneumonia.
In the present study, we observed the protective effect
on MI patients lasted for 90 days. The possible mecha-
nisms underlying these discrepancies might be related to
the differences of study designs, prescription rates of sta-
tin, commonly prescribed statins and patient characteris-
tics between studies. Although discrepancies existed, the
observations from our and previous research revealed
that statin use might be associated with prevention of
pneumonia in different patient groups.
Regarding prevention of adverse cardiovascular events,
it remains controversial whether statin therapy before an
MI event is beneficial. Some studies have reported that
chronic statin pretreatment resulted in a small infarct
area, more preserved ventricular function [7], and low
hospital mortality [8] when patients developed acute
MIs. However, Feurnau et al. recently showed that
chronic statin pretreatment was not associated with
minimal myocardial damage during MI events [20]. The
differences of baseline risk profiles between patients ex-
posed to statin pretreatment and those unexposed to
pretreatment might have affected the effects of statin
therapy [7, 8, 20]. Based on our results, statin use has
superior benefits for patients unexposed to statin pre-
treatment than for all patients with MI. The major rea-
son might be that MI patients exposed to statin
pretreatment might have a significantly greater risk pro-
file (e.g. hyperlimpidia) than patients unexposed to pre-
treatment [7, 8, 20]. Other potential reasons such as
exact type, dose, duration and compliance of statin pre-
treatment might have also contributed to the heterogen-
eity [20]. These findings provide implications for further
research on the pleiotropic effects of statins.
In our stratified analysis, statin users who were female
or had fewer comorbidities had a significantly low risk of
pneumonia. Our observations are similar to those of van
de Garde, who reported that statin use was associated
with a reduced risk of pneumonia in patients with dia-
betes who were female and had no previous pulmonary
diseases [12]. Both findings suggested that the clinical
presentation of pleiotropic effects of statins might be in-
fluenced by the individual’s risk profiles of patients. The
specific conditions that might affect the effects of statins
on the occurrence of pneumonia provide crucial infor-
mation on how a randomized controlled trial should be
designed to clarify the role of statins as an adjunctive
treatment for the prevention of pneumonia in patients
with MI.
Table 4 Statin type and the risk of pneumonia requiring hospitalization within a 90-day exposure
Controls Cases Crude OR Adjusteda OR
N N (95 % CI) P (95 % CI) P
Overall MI patients 4,778 963 - -
Statin type
Artovastatin 3,242 639 1.00 (Ref.) 1.00 (Ref.)
Fluvastatin 556 132 1.21 (0.94–1.56) 0.136 1.14 (0.85–1.52) 0.390
Simvastatin 510 109 1.04 (0.79–1.38) 0.781 1.19 (0.87–1.64) 0.283
Other 470 83 0.87 (0.65–1.17) 0.363 0.73 (0.51–1.03) 0.075
MI patients unexposed to statin pretreatment 2,683 403
Statin type
Atorvastatin 1,863 270 1.00 (Ref.) 1.00 (Ref.)
Fluvastatin 297 55 1.16 (0.71–1.90) 0.549 1.11 (0.6–2.04) 0.743
Simvastatin 278 54 0.80 (0.49–1.32) 0.386 1.12 (0.59–2.10) 0.729
Other 245 24 0.65 (0.36–1.17) 0.153 0.66 (0.31–1.41) 0.286
ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blockade, CHADS2 congestive heart failure, hypertension, age > 75 years, diabetes, previous
stroke, CI confidence interval; COPD, chronic obstructive pulmonary disease, DDD defined daily dose, DDD90 average defined daily dose within 90 days, OR odds
ratio, PPI proton pump inhibitor, Ref reference group, SD standard deviation
a Adjusted for CHASD2 score, medical conditions (diabetes mellitus, hypertension, chronic heart failure, stroke, COPD, chronic kidney disease, chronic liver disease,
Parkinson disease, and dementia) and medication use (antineoplastic drug, PPI, ACEI/ARB, antiviral drug, immunosuppressants, immunostimulants, nitrate,
antiplatelet and influenza or pneumococcal vaccine)
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In addition to time-dependent effect of statin use, our
results showed a dose-dependent relationship of the
benefits of statins that were similar to those reported by
Wang et al., who demonstrated that statins prescribed at
a medium or high DDD led to a 40–67 % reduction in
the risk of COPD exacerbation, including concurrent
pneumonia [21]. Additionally, two randomized controlled
trials showed that statins exerted an anti-inflammatory ef-
fect in a dose-dependent manner [22, 23]. These findings
raise a concern of optimal dosage of statins regarding their
anti-inflammatory and pleiotropic effects. The exact
mechanisms behind the effect of statin use on reducing
the occurrence of pneumonia have not been completely
elucidated. Statins have been shown to exert variable anti-
microbial activity against various bacterial strains [24] and
control the bacilli burden by enhancing host-induced au-
tophagy and phagosomal maturation during pathogen in-
vasion [25]. In addition, statins promote the clearance of
microparticles from lung tissues to regional lymph nodes,
attenuate recruitment and activation of alveolar macro-
phages, thereby reducing local proinflammatory cytokine
production in the lungs [26]. The results from these afore-
mentioned studies might provide possible mechanisms for
the protective benefits of statin therapy. It still remains
unclear whether different lipid-lowering abilities of statins
can be correlated to their different anti-inflammatory abil-
ities. In the present study, we observed that atorvastatin,
fluvastatin and simvastatin had similar effects on reducing
the risk of pneumonia among MI patients. Our findings
were consistent with those of Vinogradova, who demon-
strated that atorvastatin and simvastatin had similar asso-
ciations with the risk of pneumonia in the general
population [11]. These observations might provide impli-
cations for further clinical trials to compare the effects of
different statins on the risk of pneumonia.
We observed that the percentage of any use of statins
after MI in present study was only 60–70 %. Another
study which was also conducted from an administrative
database in the United States showed that 46.9 % of pa-
tients with high risk of cardiovascular disease were no
longer taking a statin at a mean time of 3 months after
drug initiation [27]. Adherence rates of statins in most
observational studies have been low, with approximately
50 % at 6 months and 25 % at 1 year [28]. Even in clin-
ical studies, adherence with statins is suboptimal, with
5-year discontinuation rate of 33 and 18 % in primary
and secondary prevention trials, respectively [29, 30].
The most common reasons contributing to discontinu-
ation and non-adherence are statin-related muscle side
effects [31]. To increase the adherence rate and benefits
of statins, especially in patients with MI and high risk of
cardiovascular disease, statins should be prescribed after
thoroughly evaluating the patient’s comorbidities, types
and dosage of statins, and concomitant medications [31].
In this study, we considered the risk of COPD and found
that COPD was associated with an increased risk of
pneumonia requiring hospitalization (crude OR = 3.43,
95 % CI = 2.82–4.18, P < 0.001). The adherence rate of
inhaled therapy in patients with COPD has been re-
ported about 41.357 % and underuse of medications was
common [32–34]. We did not analyze the adherence of
medications for COPD because the numbers of MI pa-
tients with coexisting COPD were relatively small. Fur-
ther clinical research is needed to investigate whether
concomitant adherence to statins use and COPD treat-
ment in MI patients with COPD could be an effective
treatment in reducing the incidence of pneumonia re-
quiring hospitalization.
Limitations
Our findings are subject to certain limitations. First, the
data on drug exposure were based on prescription
claims, which might not reflect actual use. Second, the
NHIRD does not have certain patient information, such
as tobacco use and ambulatory status, which might con-
tribute to the occurrence of pneumonia. Third, the
NHIRD was derived from the administrative claims
database that did not consider certain clinical informa-
tion, such as the severity and etiology of pneumonia.
Fourth, we did not further investigate the effects of spe-
cific statins. Fifth, we did not analyze the effect of con-
comitant use of statins and medications for coexisting
pulmonary comorbidities. Finally, this study was con-
ducted using a cohort of Taiwanese patients. The results
might not be generalized to other populations. Future
prospective, randomized studies on the effects of statins
are warranted to confirm our findings.
Conclusions
Statin use among patients with MI might be associated
with a decreased risk of hospitalization for pneumonia
in time- and dose-dependent manners, particularly for
patients who were unexposed to statin pretreatment or
had fewer comorbidities. Our results suggest that statin
use might be used in an adjunctive therapy in preventing
pneumonia hospitalization for patients with MI under
thorough evaluation of individual comorbidities, previ-
ous statin use and optimal dosage.
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